Manufacturers Life Insurance Company, The Lineage Cell Therapeutics, Inc. Transaction History

Manufacturers Life Insurance Company, The

$108 Billion
Q3 2024

A detailed history of Manufacturers Life Insurance Company, The transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 57,953 shares of LCTX stock, worth $34,771. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,953

Previous 57,953 -0.0%

Holding current value

$34,771

Previous $57,000 8.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.89 - $1.47 $382 - $632	-430 Reduced 0.74%	57,953 $57,000
Q4 2023 Feb 13, 2024	SELL	$0.91 - $1.35 $2,520 - $3,739	-2,770 Reduced 4.53%	58,383 $63,000
Q2 2023 Aug 11, 2023	BUY	$1.26 - $1.53 $1,883 - $2,287	1,495 Added 2.51%	61,153 $86,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $66,816 - $96,049	-59,658 Closed	0 $0
Q1 2022 Aug 11, 2023	BUY	$1.21 - $2.48 $72,186 - $147,951	59,658 New	59,658 $91,000
Q1 2022 May 20, 2022	SELL	$1.21 - $2.48 $19,856 - $40,696	-16,410 Reduced 21.57%	59,658 $92,000
Q4 2021 Feb 16, 2022	BUY	$1.84 - $2.68 $1,981 - $2,886	1,077 Added 1.44%	76,068 $186,000
Q3 2021 Nov 12, 2021	SELL	$2.26 - $2.86 $6,899 - $8,731	-3,053 Reduced 3.91%	74,991 $189,000
Q2 2021 Aug 12, 2021	BUY	$2.17 - $3.0 $169,355 - $234,132	78,044 New	78,044 $222,000
Q2 2020 Aug 10, 2020	SELL	$0.71 - $1.18 $59,138 - $98,285	-83,293 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$0.6 - $1.58 $28,074 - $73,928	46,790 Added 128.18%	83,293 $69,000
Q4 2019 Feb 14, 2020	BUY	$0.54 - $1.01 $19,711 - $36,868	36,503 New	36,503 $32,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $102M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.

Account

Manufacturers Life Insurance Company, The Lineage Cell Therapeutics, Inc. Transaction History